In pursuit of an HIV cure, Gilead jumps into a T cell-driving vaccine program with a $785M deal that triggers PhI

John Carroll

Editor & Founder

After running through a lengthy stretch watching the market downshift expectations of its cancer pipeline, Gritstone Oncology has erupted with a quick set of advances …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In pursuit of an HIV cure, Gilead jumps into a T cell-driving vaccine program with a $785M deal that triggers PhI

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Stem cell startup spun out of George Church’s lab raises $75M

Breaking down silos with a new quantitative approach to drug development

In pur­suit of an HIV cure, Gilead jumps in­to a T cell-dri­ving vac­cine pro­gram with a $785M deal that trig­gers PhI

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

In pursuit of an HIV cure, Gilead jumps into a T cell-driving vaccine program with a $785M deal that triggers PhI